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Abstract 
Background: Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and erythema multiforme (EM) are 
immunologically‑mediated dermatological disorders commonly triggered by drug exposure and/or other external 
agents. We aimed to characterise SJS/TEN‑ and EM‑drug‑related hospitalisations in a nationwide administrative data‑
base, focusing on demographic and clinical characteristics, and in the most frequently implicated drug classes.
Methods: We analysed all drug‑related hospitalisations with associated diagnosis of SJS/TEN or EM in Portuguese 
hospitals between 2009 and 2014. We compared gender, age, comorbidities, length of stay, and in‑hospital mortality 
and estimated the number of episodes per million packages sold of drug classes. Predictors of in‑hospital mortality 
were investigated in both conditions by logistic regression.
Results: There were 132 SJS/TEN‑related and 122 EM‑related hospitalisations. Incidence and in‑hospital mortality 
of SJS/TEN episodes (24.2%) were consistent with previous studies. HIV co‑infection was more common among SJS/
TEN hospitalisations (9 vs. 2% with EM; P = 0.009). Liver disease, advanced age, and a TEN diagnosis, were significantly 
associated with higher risk of mortality in patients with SJS/TEN. The highest numbers of SJS/TEN and EM episodes 
per million drug packages sold were observed for antivirals (8.7 and 1.5, respectively), antineoplastic/immunosuppres‑
sive drugs (5.6 and 3.9, respectively) and hypouricaemic drugs (5.0 and 2.4, respectively).
Conclusions: SJS/TEN in‑hospital mortality is high, and its risk factors include advanced age, liver disease, and TEN 
diagnosis. The drug classes most frequently associated with these conditions include antivirals, hypouricaemic drugs 
and antineoplastic/immunosuppressive drugs. Administrative databases seem useful in the study of SJS/TEN drug‑
related hospitalisations, yielding results consistent with previous studies and on a nationwide basis.
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Background
Severe cutaneous adverse reactions (SCARs) are an 
example of severe type B adverse drug reactions, and 
are associated with high morbidity and mortality [1]. 
SCARs encompass three distinct clinical entities: (1) the 
spectrum of Stevens–Johnson syndrome/toxic epider-
mal necrolysis (SJS/TEN), (2) acute generalised exan-
thematous pustulosis (AGEP), and (3) drug reactions 
with eosinophilia and systemic symptoms (DRESS) [2, 
3]. Diagnosis of these conditions is further complicated 
by the existence of overlap syndromes, characterised by 
the coexistence of features from different entities [4]. The 
SJS/TEN spectrum is the most common and lethal of all 
SCARs. It associates with a mortality of up to 40%, ver-
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SJS/TEN is characterised by cutaneous detachment and 
blister formation—in SJS, skin detachment affects less 
than 10% of the body surface area, while TEN requires 
involvement of over 30% [7, 8]. Cases with 10–30% of 
body surface area involvement are classified as SJS–TEN 
overlap syndrome [7, 8].
Until recently, there was widespread belief that ery-
thema multiforme (EM) major was a milder form of 
SJS/TEN spectrum [9, 10]. However, this assumption 
has now been largely abandoned—most cases of EM 
are associated with herpes virus infections, while only a 
minority are deemed to be caused by drugs [9–12]. Dis-
tinction between EM and SJS/TEN is crucial since the 
latter is associated with much greater severity and higher 
mortality [9], and as these conditions have different treat-
ment approaches. Clinically, SJS/TEN is characterised by 
macules or flat atypical target lesions with widespread 
distribution or preferential trunk involvement, which 
rapidly evolve as a blistering disorder of the skin and 
mucosal surfaces. Conversely, EM typically presents with 
predominantly acral target lesions [11, 13]. Nevertheless, 
atypical presentations can make it difficult to distinguish 
between the two entities [13], especially at the beginning 
of the clinical presentation and when there is a history of 
previous drug exposure.
An improved knowledge on the risk factors associ-
ated with SJS/TEN might thus facilitate the distinction 
between SJS/TEN and EM, as well as provide clues con-
cerning the pathophysiology of this condition [11, 14, 15]. 
However, is spite of its severity, the epidemiology of SJS/
TEN remains insufficiently studied [16], in part because 
its rarity renders traditional case–control or cohort stud-
ies particularly time- and resource-consuming. On the 
other hand, administrative databases are being increas-
ingly used in the assessment of such rare and very rare 
conditions [16]. Therefore, in this study, we analysed a 
nationwide administrative database with the aim of char-
acterising drug-related hospitalisations in patients with 
SJS/TEN, with a focus on gender and age, comorbidities, 
length of hospital stay, in-hospital mortality, and respon-
sible drug classes. We compared these results to those 
observed for patients with a diagnosis of drug-related 
EM, so that we could infer whether in administrative 
databases SJS/TEN cases are mostly distinguished from 
other often confused conditions.
Methods
We used a database provided by the Portuguese Cen-
tral Health System Administration containing data for 
all hospitalisations in mainland Portugal public hospi-
tals. Anonymity was maintained for all hospitals and 
patients. For each episode, we had access to the main 
diagnosis (clinical condition responsible for the patient’s 
admission), up to 19 accompanying diagnoses, and up 
to 5 external causes of injury and poisoning (including 
adverse drug effects). Both diagnoses and external causes 
had been coded with ICD-9-CM codes after discharge; 
thus, both community cases requiring hospitalisation 
and in-hospital cases were identified. Coding in Portugal 
is standardised and performed by doctors with specific 
training, and internal and external auditing is regularly 
performed to ensure proper coding [17].
We analysed all hospitalisations with a main or sup-
plementary diagnosis of SJS/TEN (ICD-9-CM codes 
695.13–695.15) and an associated E code (ICD-9-CM 
codes E930.x–E949.x for adverse drug reactions—ICD-
9-CM codes are listed in Additional file 1: Table S1—each 
code corresponds to the drug class deemed responsible 
for the reaction according to the responsible physician). 
We separately analysed hospitalisations with an associ-
ated diagnosis of SJS (695.13), SJS–TEN overlap (695.14), 
and TEN (695.15) to allow for comparison between these 
conditions. Since these three codes were introduced in 
October 2008 [18], we only analysed hospitalisations 
between January 2009 and December 2014. SJS/TEN 
episodes were compared with hospitalisations with main 
or supplementary diagnosis of EM (ICD-9-CM codes 
695.10, 695.11, 695.12, and 695.19) and an associated E 
code.
We calculated the number of hospitalisations of SJS/
TEN and EM per million inhabitants based on data pub-
lished by the Portuguese National Institute of Statistics 
[19]. This rate probably provides a good estimation of the 
6-year incidence of SJS/TEN in Portugal as the severity of 
this condition entails almost all patients to be hospital-
ised in public hospitals.
We compared gender, age, and comorbidities between 
episodes with a diagnosis of EM and hospitalisations with 
a diagnosis of SJS/TEN; the three clinical entities of the 
latter (SJS, SJS–TEN overlap, and TEN) were also com-
pared with each other. We compared the frequency of 
comorbidities potentially associated with an increased 
risk of SJS/TEN (whether directly or indirectly), namely 
chronic kidney disease, hypertension, heart failure, dia-
betes, HIV infection, and liver disease (Additional file 1: 
Table  S1). Chronic kidney disease is associated with an 
increased risk of allopurinol-induced SJS/TEN [20]. As 
the use of diuretics is also associated with the latter con-
dition [21], we also assessed conditions whose treatment 
frequently requires the use of diuretics, namely hyper-
tension, heart failure, and diabetes. HIV infection was 
assessed, as the risk of SJS/TEN is known to be higher 
among  HIV+ patients [22]. Liver disease may also be a 
risk factor for SJS/TEN, particularly in regard to chronic 
viral hepatitis [23]. We also evaluated length of hospital 
stay, readmission rate, and in-hospital mortality. To study 
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hospital readmissions, we identified individual patients 
admitted between 2009 and 2014 and followed them up 
until the end of the study period. Registries in our data-
base had been anonymised and, therefore, individual 
patients were identified according to their gender, birth-
date and residence—two episodes were deemed to have 
occurred with the same patient whenever the registered 
inpatient’s gender, birthdate and residence were equal, 
and the registered diagnoses were similar.
For each clinical entity, we compared the frequency of 
the drug classes recorded as implicated in the adverse 
drug reactions. In the dataset used, adverse drug reac-
tions are identified by E codes, each of which corre-
sponds to a different class of drugs. In addition, based 
on information provided by the Portuguese Authority of 
Medicines and Health Products (INFARMED), we esti-
mated the number of EM and SJS/TEN episodes per mil-
lion packages of drugs sold [24–28]. For this estimate, we 
excluded data from 2009 due to the risk of underreport-
ing, as the ICD-9-CM SJS/TEN codes were introduced 
that year.
Categorical variables were compared using the Chi 
square test and the Fisher exact test. Continuous vari-
ables were analysed using the Mann–Whitney U test 
and the Kruskal–Wallis test. P values < 0.05 were consid-
ered statistically significant. To analyse risk factors sig-
nificantly associated with in-hospital mortality (both for 
EM and SJS/TEN), we used logistic regression models. 
We performed univariable analyses assessing the asso-
ciation between in-hospital mortality and gender, age, 
length of hospital stay, SJS/TEN entities (SJS, SJS–TEN 
overlap, and TEN), hypertension, diabetes, heart failure, 
chronic kidney failure, liver disease, and HIV status. Var-
iables with marginal association in the univariate analy-
sis (P < 0.20) were included in multivariable models. The 
models were assessed by their area under the receiver 
operating characteristics curve (AUC-ROC) and by the 
Hosmer–Lemeshow goodness-of-fit test; multicollin-
earity was assessed using variance inflation factor. The 
results of the univariable and multivariable analyses are 
expressed as odds ratio (OR) with 95% confidence inter-
vals (95% CI), and P values. All statistical analyses were 
performed using SPSS version 22.0  (IBM®SPSS® Statis-
tics, Armonk, NY:IBM Corp.).
For this study, Ethics Committee Approval and 
Informed consent were not needed, as all data had previ-
ously been anonymised.
Results
From 2009 to 2014, we recorded 122 hospitalisations 
with an associated diagnosis of EM (main diagnosis in 
34 cases) and 132 hospitalisations with an associated 
diagnosis of SJS/TEN (main diagnosis in 89 cases). This 
corresponds to a 6-year incidence of 13.2 hospitalisa-
tions with EM and 12.2 hospitalisations with SJS/TEN 
per million inhabitants (Table 1). In 2014, we observed a 
1-year incidence of 2.1 EM hospitalisations and 3.8 SJS/
TEN hospitalisations per million inhabitants, while the 
1-year incidences in 2009 were of 3.2 EM hospitalisations 
and 0.7 SJS/TEN hospitalisations per million inhabitants 
(Additional file 2: Table S2), suggesting a learning effect 
as SJS/TEN codes were firstly used in 2009.
SJS (n =  73) accounted for 55% of all SJS/TEN hos-
pitalisations, while SJS–TEN overlap (n  =  18) and 
TEN (n =  41) accounted for 14% and 31%, respectively 
(Table 1). Patient readmissions accounted for 3% (n = 7) 
of all hospitalisations (2% for EM vs. 4% for SJS/TEN). All 
readmissions occurred within 1  year of the first hospi-
talisation and most cases (all EM readmissions and 33% 
of SJS/TEN readmissions) were due to exposure to the 
same drug class. A majority of hospitalisations occurred 
in females, both for EM (65%) and SJS/TEN (55%). The 
median age in each case was 63 years. Six percent (n = 7) 
of EM episodes and 8% (n = 10) of SJS/TEN episodes (8 
with SJS and 2 with TEN diagnosis) occurred in children, 
and 43% and 70% occurred, respectively, in girls. No 
significant differences were observed for gender or age 
distribution between the distinct SJS/TEN entities (SJS, 
SJS–TEN overlap, and TEN).
HIV co-infection was more common in hospitalisa-
tions with associated diagnosis of SJS/TEN (9%) than 
with EM (2%) (P = 0.009). No significant differences were 
observed for the frequency of any of the other comorbid-
ities studied.
The median length of hospital stay was 10  days for 
EM versus 15 days for SJS/TEN (P = 0.007). Within the 
SJS/TEN group, TEN episodes were associated with the 
shortest median length of stay (14  days); however, con-
sidering non-fatal cases only, TEN was associated with a 
median length of stay of 22 days.
A fatal outcome was reported for 7% of hospitalisa-
tions with associated diagnosis of EM and for 24% of 
SJS/TEN episodes (P  <  0.001). In the SJS/TEN group, 
TEN had the highest proportion of fatal cases (44%), 
followed by SJS (16%), and SJS–TEN overlap (11%) 
(P  =  0.002). No fatal cases were registered among 
paediatric patients. Variables significantly associ-
ated with in-hospital mortality in hospitalisations 
with a diagnosis of SJS/TEN after multivariable analy-
sis included advanced age (OR 1.1 per year; 95% CI 
1.0–1.1; P  =  0.002), a diagnosis of liver disease (OR 
7.9; 95% CI 1.2–50.7; P  =  0.031), and TEN (OR 6.5; 
95% CI 2.3–18.8; P  =  0.001) (Table  2). For EM, the 
variables significantly associated with in-hospital mor-
tality were advanced age (OR 1.1 per year; 95% CI 
1.0–1.2; P = 0.005) and male gender (OR 23.9; 95% CI 
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3.4–168.6; P  =  0.001). The multivariable models for 
SJS/TEN and EM hospitalisations had an AUC-ROC 
of 0.843 and 0.912, respectively. The Hosmer–Leme-
show goodness-of-fit test did not evidence lack of fit 
in the multivariable model for SJS/TEN (P = 0.942) or 
EM (P = 0.995). The models did not show evidence of 
multicollinearity.
Drug classes most frequently associated with adverse 
reactions in hospitalised patients with SJS/TEN were 
antibiotics (26%), uric acid metabolism drugs (20%), and 
anticonvulsants (17%) (Table  3). The same drug classes 
were identified in cases of EM: 30% for antibiotics, 17% 
for uric acid metabolism drugs, and 11% for anticonvul-
sants. In paediatric patients, antibiotics were responsible 
for the greatest proportion of adverse reactions in EM 
(57%) and SJS/TEN (30%) hospitalisations. The two regis-
tered cases of TEN in children were associated with anti-
viral and psychotropic drugs.
Eighty-eight percent of episodes with reported adverse 
reactions to antivirals were in  HIV+ patients. In hospi-
talisations with associated diagnosis of EM, chronic kid-
ney disease was more common in episodes with adverse 
reactions attributed to uric acid metabolism drugs 
(P =  0.006). In hospitalisations with SJS/TEN, however, 
chronic kidney disease was significantly associated with 
adverse reactions to antibiotics (P = 0.023). Liver disease 
was not significantly associated with adverse reactions to 
any of the drug classes analysed.
The drug classes associated with a higher number of 
SJS/TEN episodes per million packages sold were anti-
viral drugs (8.7 episodes), followed by anti-neoplastic/
immunosuppressive drugs (5.6), uric acid metabolism 
drugs (5.0), and anticonvulsants (1.2). The corresponding 
classes for EM were anti-neoplastic/immunosuppressive 
drugs (3.9 episodes), followed by uric acid metabolism 
drugs (2.4) and antiviral drugs (1.5)(Table 4).
Table 1 Demographic and clinical characteristics of hospitalised patients with an associated diagnosis of erythema 
multiforme (EM) or Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN); Mainland Portugal, 2009–2014 
(n = 254 hospitalisations)
a Encompasses 5 cases of EM minor, 11 cases of EM major, 10 cases of other forms of EM, and 96 cases of unspecified EM
b Stevens–Johnson and toxic epidermal necrolysis overlap syndrome
c Includes all episodes, including those resulting in the death of patients
Characteristics Cutaneous adverse reactions SJS/TEN
EMa (N = 122) SJS/TEN (N = 132) P value Stevens–Johnson 
Syndrome (N = 73)
SJS–TEN  overlapb 
(N = 18)
Toxic epidermal 
necrolysis (N = 41)
P value
Episodes as main 
diagnosis—n (%)
34 (27.9) 89 (66.4) 45 (61.6) 14 (77.8) 30 (68.3)
6‑years incidence (per 
million inhabitants)
12.2 13.2 7.3 1.8 4.1
Gender—n (%)
 Male 43 (35.2) 60 (45.5) 0.098 34 (46.6) 9 (50.0) 17 (41.5) 0.798
 Female 79 (64.8) 72 (54.5) 39 (53.4) 9 (50.0) 25 (58.5)
Age (years)
 Median (percentile 
25–75)
63 (44–77) 63 (45–75) 0.903 64 (46–79) 57 (34–72) 65 (48–74) 0.492
Comorbidities
 Hypertension 39 (32.0) 46 (34.8) 0.627 29 (39.7) 5 (27.8) 12 (29.3) 0.422
 Diabetes 19 (15.6) 22 (16.7) 0.813 13 (17.8) 4 (22.2) 5 (12.2) 0.589
 Heart failure 10 (8.2) 13 (9.8) 0.647 8 (11.0) 3 (16.7) 2 (4.9) 0.272
 Chronic kidney 
disease
12 (9.8) 15 (11.4) 0.693 7 (9.6) 4 (22.2) 4 (9.8) 0.340
 Liver disease 11 (9.0) 10 (7.6) 0.677 4 (5.5) 3 (16.7) 3 (7.3) 0.203
  Acute toxic 
hepatitis
7 (5.7) 6 (4.5) 0.882 2 (2.7) 2 (11.1) 2 (4.9) 0.269
 HIV 2 (1.6) 12 (9.1) 0.009 8 (11.0) 3 (16.7) 1 (2.4) 0.115
Length‑of‑stayc (days)
 Median (percentile 
25–75)
10 (5–20) 15 (7–28) 0.007 15 (7–23) 23 (9–36) 14 (7–28) 0.456
In‑hospital mortal‑
ity—n (%)
9 (7.4) 32 (24.2) < 0.001 12 (16.4) 2 (11.1) 18 (43.9) 0.002
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Discussion
We used an administrative database to assess SJS/TEN 
and EM hospitalisations, and found that hospitalisa-
tions in patients with SJS/TEN were associated with 
significantly longer hospital stays and higher in-hospital 
mortality than hospitalisations in patients with associ-
ated diagnosis of EM, highlighting the need to accurately 
distinguish between these two clinical conditions. Drug 
classes responsible for the greatest proportion of adverse 
reactions in patients with SJS/TEN were antibiotics, uric 
acid metabolism drugs, and anticonvulsants. In-hospital 
mortality in SJS/TEN cases was significantly associated 
with liver disease, advanced age, and TEN diagnosis.
Most hospitalisations with associated diagnosis of SJS/
TEN and EM occurred in females and older patients, a 
finding not totally consistent with several other studies, 
which found EM to be more frequent among males and 
younger patients [11, 29]. One the one hand, it is possi-
ble to hypothesise that this study predominantly assessed 
severe cases of EM, as most cases of this condition do 
not require hospitalisation (i.e. SJS/TEN episodes regard-
less of their severity were only compared with the most 
severe EM cases). However, it is also possible to infer that 
a substantial number of cases classified with a diagnosis 
of “EM” might actually consist of misclassified cases. In 
fact, the diagnosis of “drug-related EM” appears to be 
over-attributed [30]. A recent review found that, from 
36 articles published from 2010 to 2016 and describing 
putative cases of drug-related EM, only 6 described cases 
compatible with probable/definite EM [30].
In our database analysis, HIV co-infection was signifi-
cantly more common among SJS/TEN hospitalisations. 
Previous studies have found that  HIV+ patients have a 
higher risk of developing SJS and TEN [22]. In fact,  HIV+ 
patients are more likely to use some of the drugs most 
frequently implicated in SJS/TEN, such as antiretrovi-
rals, sulfamethoxazole/trimethoprim, and antitubercu-
losis drugs, and they often use them at higher doses [31, 
32]. Secondly, these patients have a decreased number of 
skin  CD4+ regulatory T cells and appear to have altered 
drug metabolism [31, 32]. HIV might also contribute to 
the pathogenesis and local cytotoxic mechanisms of SJS/
TEN, as suggested by the presence of HIV antigens in the 
skin lesions of patients with these reactions [33].
The frequency of fatal cases in our series is consistent 
with other studies [34, 35]. Advanced age was identi-
fied as a risk factor for in-hospital mortality among SJS/
TEN episodes; in fact, advanced age is an independent 
Table 2 Results from binomial logistic regression with in-hospital mortality as the dependent variable
OR odds ratio, CI confidence interval
a Adjusted for gender, age, and hypertension
b Adjusted for age, Stevens–Johnson syndrome, toxic epidermal necrolysis, heart failure, chronic kidney disease, and liver disease
c Values per year
d Values per day
e No fatal cases were registered
f Reference category
Erythema multiforme Stevens–Johnson syndrome/toxic epidermal necroly-
sis
Crude OR (95% CI);  
P value
Adjusted OR (95% CI);  
P  valuea
Crude OR (95% CI);  
P value
Adjusted OR (95% CI); 
P  valueb
Male gender 7.5 (1.5–37.9); 0.015 23.9 (3.4–168.6); 0.001 1.4 (0.6–3.1); 0.432 –
Age 1.1c (1.0–1.2); 0.011 1.1c (1.0–1.2); 0.005 1.1c (1.0–1.1); < 0.001 1.1c (1.0–1.1); 0.002
Length of stay 1.0d (0.9–1.1); 0.750 – 1.0d (1.0–1.0); 0.398 –
Hypertension 2.9 (0.7–11.5); 0.129 0.7 (0.1–4.4); 0.721 0.9 (0.4–2.0); 0.729 –
Diabetes 1.6 (0.3–8.4); 0.571 – 1.7 (0.6–4.6); 0.316 –
Heart failure 1.4 (0.2–12.9); 0.742 – 4.6 (1.4–15.0); 0.011 4.1 (0.9–18.2); 0.060
Chronic kidney disease 2.9 (0.5–16.1); 0.213 – 2.5 (0.8–7.6); 0.117 0.7 (0.2–3.1); 0.725
Liver disease e e 3.7 (1.0–13.7); 0.051 7.9 (1.2–50.7); 0.031
HIV e e 0.6 (0.1–3.0); 0.562 –
Clinical entity




– – 0.6 (0.1–3.1); 0.577 0.4 (0.1–3.4); 0.437
 Toxic epidermal necrolysis – – 4.0 (1.7–9.5); 0.002 6.5 (2.3–18.8); 0.001
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risk factor in the SCORTEN severity scale [36, 37]. Liver 
disease was also found to be associated with increased 
in-hospital mortality in our analysis, and while hepatic 
involvement in SCARs is associated with high mortality 
[38], chronic viral hepatitis has also been hypothesised by 
some authors to be a risk factor for TEN [23]. Impaired 
drug metabolism secondary to chronic liver disease could 
also enhance the risk of a fatal outcome.
The drug classes responsible for adverse reactions most 
frequently associated with SJS/TEN included antibiot-
ics, antivirals, anticonvulsants, and uric acid metabolism 
drugs. Although we were not able to identify the specific 
culprit drugs within these groups, the latter include 
drugs that have frequently been previously described to 
be associated with SCARs, such as allopurinol, and lamo-
trigine [14, 15]. After adjusting for the number of drug 
packages sold, we also found a high rate of hospitalisa-
tions associated with adverse reactions to antineoplastic 
and immunosuppressive drugs, supporting some under-
lying immune deregulation associated with malignan-
cies or autoimmune diseases [14]. While many cases of 
EM and SCARs have been reported following the use 
of several of these drugs, the underlying immunological 
mechanisms are still only partially identified [20, 39, 40]. 
Table 3 Drug classes deemed responsible for the cutaneous adverse reactions occurred in the context of hospitalisations 
with an associated diagnosis of erythema multiforme (EM) or Stevens–Johnson syndrome/toxic epidermal necrolysis 
(SJS/TEN); Mainland Portugal, 2009–2014 (n = 254 hospitalisations)
a Includes, among others, macrolides, tetracyclines, and cephalosporins
b These were the only drugs of the class “primarily systemic agents” in which cutaneous adverse reactions were registered
c These were the only drugs of the class “water, mineral, and uric acid metabolism drugs” in which cutaneous adverse reactions were registered
d There were no cutaneous adverse reactions associated with use of drugs belonging to the classes “other central nervous system depressants and anesthetics”, 
“central nervous system stimulants”, “drugs primarily affecting the autonomic nervous system” and “agents primarily affecting gastrointestinal system”
Drug class—n (%) Cutaneous adverse reactions SJS/TEN
EM (N = 122) SJS/TEN (N = 132) P value SJS (N = 73) SJS–TEN  overlapa (N = 18) TEN (N = 41) P value
Antibiotics 36 (29.5) 34 (25.8) 0.504 18 (24.7) 6 (33.3) 10 (24.4) 0.731
 Penicillins 9 (7.4) 9 (6.8) 0.862 2 (2.7) 4 (22.2) 3 (7.3) 0.016
 Other specified  antibioticsa 22 (18.0) 22 (16.7) 0.774 14 (19.2) 1 (5.6) 7 (17.1) 0.380
 Unspecified antibiotics 4 (3.3) 2 (1.5) 0.431 1 (1.4) – 1 (2.4) 0.999
Other anti‑infectives 10 (8.2) 18 (13.6) 0.167 12 (16.4) 4 (22.2) 2 (4.9) 0.117
 Sulfonamides 4 (3.3) 8 (6.1) 0.296 5 (6.8) 2 (11.1) 1 (2.4) 0.285
 Antimycobacterial drugs 1 (0.8) 2 (1.5) 0.999 2 (2.7) – – 0.654
 Antiviral drugs 1 (0.8) 7 (5.3) 0.068 4 (5.5) 2 (11.1) 1 (2.4) 0.340
Hormones and synthetic sub‑
stitutes
7 (5.7) 7 (5.3) 0.879 5 (6.8) 2 (11.1) – 0.126
Antineoplastic and immunosup‑
pressive  drugsb
13 (10.7) 7 (5.3) 0.114 3 (4.1) 1 (5.6) 3 (7.3) 0.759
Agents primarily affecting blood 
constituents
– 4 (3.0) 0.123 2(2.7) 1 (5.6) 1 (2.4) 0.611
Analgesics, antipyretics, and 
antirheumatics
11 (9.0) 7 (5.3) 0.249 3 (4.1) 1 (5.6) 3 (7.3) 0.759
Anticonvulsants 13 (10.7) 22 (16.7) 0.165 12 (16.4) 2 (11.1) 8 (19.5) 0.726
Sedatives and hypnotics – 1 (0.8) 0.999 – 1 (5.6) – 0.136
Psychotropic agents 2 (1.6) 4 (3.0) 0.685 2 (2.7) – 2 (4.9) 0.789
Agents primarily affecting the 
cardiovascular system
2 (1.6) 2 (1.5) 0.999 1 (1.4) – 1 (2.4) 0.999
Uric acid metabolism  drugsc 21 (17.2) 26 (19.7) 0.611 17 (23.3) 2 (11.1) 7 (17.1) 0.447
Agents primarily acting on the 
smooth and skeletal muscles 
and respiratory system
1 (0.8) – 0.480 – – –
Agents primarily affecting skin 
and mucous membrane, oph‑
thalmological, otorhinolaryn‑
gological and dental drugs
1 (0.8) – 0.480 – – –
Other and unspecified drugs 
and medicinal  substancesd
9 (7.4) 12 (9.1) 0.620 7 (9.6) – 5 (12.2) 0.368
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Some antineoplastic drugs (e.g., EGFR tyrosine kinase 
inhibitors) interfere with keratinocyte proliferation, dif-
ferentiation, and migration, and, thus, might facilitate the 
development of more severe SCARs. Similarly, radiother-
apy could also increase the risk of EM and SCARs, pos-
sibly by inhibiting hepatic enzymes responsible for drug 
metabolism [41].
The use of an administrative database to study rare 
conditions such as SJS/TEN might have some advantages 
comparing to traditional case–control and cohort studies. 
Although these are the ideally preferred studies, case–
control and cohort studies are usually resource-consum-
ing and difficult to conduct, particularly on a nationwide 
and frequent basis [16, 42–44]. Additionally, administra-
tive database studies may yield results consistent with 
these registry-based studies; for instance, the results 
described in our study concerning SJS/TEN demographic 
characteristics and mortality are similar with those of a 
recent study conducted in Italy [14]. On the other hand, 
in the lack of other registries, administrative database 
studies might feasibly complement pharmacovigilance 
studies and help to detect regional differences. The com-
prehensiveness of administrative databases regarding this 
condition is another important advantage—due to its 
severity, SJS/TEN is a condition requiring hospitalisation; 
additionally, the nationwide scope of the database allows 
for an overcome of possible biases related to the assess-
ment of participants of a single region [16].
Nevertheless, although coding is standardised and fre-
quently audited in Portugal, it should be noted that these 
databases might be incomplete or inaccurate [42]. A sys-
tematic review found that only 53–60% of ICD-9-CM 
code 695.1 reports consisted of validated cases of EM, SJS 
and TEN [45], while Davis et al. [18] found that, among 
inpatients, ICD-9-CM codes 695.13–695.15 correctly 
identified 50% of patients, and up to 57–92% when only 
patients hospitalised for three or more days were con-
sidered. While, in our study, we did not select patients 
according to their length of stay, only three patients had 
been hospitalised for less than 3 days (two of them died 
when hospitalised). Additionally, we identified drug 
hypersensitivity cases by using a combination of both 
ICD-9-CM diagnostic codes and E codes. According to 
Saff et  al. [46], this combination identifies drug allergy 
patients more accurately than the use of a single code, but 
it underestimates the true incidence of drug allergic reac-
tions. This algorithm lacks, however, validation regarding 
episodes with associated diagnosis of drug-related EM. 
In fact, not only there are several drug-related conditions 
which do not have a specific ICD-9-CM code (e.g. DRESS 
and AGEP), but also some heterogeneous drug-induced 
skin-eruptions may present as EM-like and, therefore, 
might be misclassified as EM [47, 48]. While these condi-
tions do not have a specific ICD-10 code either [49], they 
are planned to have a specific ICD-11 code [50, 51]—in 
fact, with the development and adoption of ICD-11, the 
accuracy of administrative databases in the assessment of 
SCARs may improve, as a greater diversity of diagnosis 
procedures, drugs (and not only drug classes) and clini-
cal entities have been ascribed specific codes—EJ00-EJ18 
codes concern “adverse cutaneous reactions to medi-
cation” and include, among others, specific codes for 
DRESS, AGEP and fixed drug eruption). Additionally, it 
is paramount to ensure the validity of the hospital dis-
charge codes for EM [18], as well as to educate clinicians 
on the differential diagnoses of drug-related skin disor-
ders [30].
Another major limitation concerns the impossibil-
ity of identifying the specific drugs associated with each 
episode. Thus, it is only possible to speculate about the 
Table 4 Number of hospitalisations with an associated diagnosis of erythema multiforme (EM) and Stevens–Johnson 
syndrome/toxic epidermal necrolysis (SJS/TEN) per million sold packages of drug classes involved in adverse reactions; 
Mainland Portugal, 2010–2014 (n = 215 hospitalisations)
NPS number of drug packages sold
Drug class EM (N = 90) SJS/TEN (N = 125)
Antibiotics (NPS = 37,311,945) 0.75 0.88
Antiviral drugs (NPS = 686,221) 1.46 8.74
Hormones and synthetic substitutes (NPS = 69,570,259) 0.08 0.10
Antineoplastic and immunosuppressive drugs (NPS = 1,787,045) 3.92 5.60
Agents primarily affecting blood constituents (NPS = 37,608,542) – 0.11
Analgesics, antipyretics, and antirheumatics (NPS = 71,419,516) 0.12 0.10
Anticonvulsants (NPS = 16,305,856) 0.43 1.17
Psychotropic agents (NPS = 100,008,577) 0.01 0.03
Agents primarily affecting the cardiovascular system (NPS = 198,300,264) 0.01 0.01
Uric acid metabolism drugs (NPS = 5,007,028) 2.40 4.99
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identity of the culprit drugs. For instance, it is highly 
probable that most hypersensitivity reactions to uric acid 
metabolism drugs were due to allopurinol, while most 
cutaneous reactions to antivirals were probably asso-
ciated with antiretroviral drugs, since these reactions 
mostly occurred in  HIV+ patients. We also lack informa-
tion on the specific clinical presentation of each episode, 
criteria used by the physicians to deem a specific drug 
class responsible for the corresponding reactions, co-
occurrence of herpes reactivation and patient ethnicity 
or birthplace. Another possible limitation concerns the 
indirect method used to identify hospital readmissions 
(based on inpatients’ gender, birth date and residence). 
Although this method does not identify distinct patients 
with complete certainty, we confirmed that episodes 
identified as readmissions and the respective “first admis-
sions” had a similar set of associated diagnoses and, for 
the cases occurred in the same hospital, an equal hospi-
tal-specific inpatient identifier number.
Conclusions
In this administrative database-analysis, SJS and TEN 
were associated with higher in-hospital mortality and 
longer hospital stays than other drug-related mucocu-
taneous conditions. In hospitalisations with a diagnosis 
of drug-related SJS or TEN, an increased risk of in-hos-
pital mortality was associated with advanced age, with 
a TEN diagnosis, and liver disease. Our findings pro-
vide an epidemiological characterisation of SJS/TEN 
hospitalisations, as well as an identification of factors 
significantly associated with higher in-hospital mortal-
ity. This epidemiological knowledge might prove useful 
for performing an earlier diagnosis of SJS/TEN, allow-
ing for an earlier start of the most adequate therapy; 
additionally, identifying factors associated with higher 
fatality will be essential for defining the most appropri-
ate measures to prevent fatal outcomes. These results 
suggest that administrative databases are useful in the 
assessment of SJS/TEN drug-related hospitalisations in a 
nationwide basis, allowing for epidemiological studies to 
be conducted in a frequent- and low-resource-consum-
ing basis. While this may be particularly advantageous 
for obtaining knowledge on SJS/TEN and for health-
care planning, further studies on this methodological 
approach are needed.
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